Genetics Quiz: Carrier Screening And Counseling

What this quiz covers

This quiz focuses on Carrier Screening And Counseling, giving you a quick way to practice the rules, question types, and explanations that matter most for Genetics.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. CVS is a screening test performed on the pregnant person's blood, while PGT is a diagnostic test performed on the fetus.
2. PGT can only determine carrier status, whereas CVS can determine if the fetus is affected, a carrier, or unaffected.
3. Both PGT and CVS are performed after 15 weeks of gestation to provide a definitive diagnosis of the condition in the fetus.
4. PGT is used to test embryos for the condition before a pregnancy is established, while CVS is a diagnostic test performed during an established pregnancy. (correct answer)

Explanation: When you encounter questions about prenatal genetic testing, focus on the timing of each procedure and whether a pregnancy has been established. Understanding the sequence of reproductive events is crucial here. PGT (Preimplantation Genetic Testing) occurs during IVF procedures before any embryo is transferred to the uterus. Embryos are created through fertilization in the laboratory, and a few cells are removed from each embryo for genetic analysis. Only embryos without the recessive condition are selected for transfer, preventing an affected pregnancy from ever being established. This allows the couple to avoid the difficult decision of pregnancy termination. CVS (Chorionic Villus Sampling), on the other hand, is performed between 10-13 weeks of an established pregnancy. A sample of placental tissue (chorionic villi) is obtained and analyzed to determine the fetus's genetic status. Since the pregnancy already exists, if the fetus is affected, the couple faces the decision of whether to continue or terminate. Answer D correctly captures this fundamental distinction: PGT prevents affected pregnancies, while CVS diagnoses them after they're established. Answer A is wrong because CVS involves sampling placental tissue, not maternal blood, and both are diagnostic tests. Answer B reverses the capabilities - both tests can provide complete genetic information about the condition. Answer C incorrectly states both occur after 15 weeks; CVS is performed earlier (10-13 weeks) and PGT occurs before pregnancy entirely. Remember: the key distinguisher is pregnancy establishment - PGT happens before, CVS happens during.

Question 2

1. the increased likelihood of identifying carriers for conditions with mild or variable phenotypes. (correct answer)
2. the high cost of genetic sequencing technology.
3. the potential for identifying non-paternity.
4. the difficulty in calculating residual risk due to imperfect detection rates.

Explanation: When evaluating ethical challenges in genetic screening, you need to distinguish between issues that exist in all forms of screening versus those that are amplified or uniquely created by expanded approaches. Expanded carrier screening (ECS) creates a fundamental ethical dilemma by casting an unprecedentedly wide net. When you test for hundreds of conditions simultaneously, you inevitably identify carriers for diseases with mild symptoms, late onset, or highly variable expression. This creates counseling challenges about conditions that may never significantly impact quality of life, forcing difficult decisions about reproductive choices based on uncertain outcomes. The sheer volume of results in ECS makes encountering these ambiguous findings nearly inevitable, unlike targeted single-disease screening where such scenarios are rare. This makes option A correct. Option B is incorrect because cost issues affect both single-disease and expanded screening - it's not uniquely problematic for ECS. Option C misses the mark because non-paternity discovery is equally likely (or unlikely) whether testing one gene or many, since it depends on inheritance patterns, not panel size. Option D represents a technical challenge present in all genetic testing - imperfect detection rates and residual risk calculations exist whether you're screening for one condition or hundreds. Remember that "expanded" or "comprehensive" screening questions often focus on ethical issues created by information overload and uncertain clinical significance. The key principle is that more testing doesn't always mean better outcomes when it generates results of questionable actionability.

Question 3

1. The challenge of distinguishing clinically significant alleles from benign variants that can confound screening tests. (correct answer)
2. The phenomenon of variable expressivity, where individuals with the same genotype show different phenotypes.
3. The importance of using population-specific carrier frequencies in risk assessment.
4. The principle of mosaicism, where an individual has two or more genetically different cell lines.

Explanation: When you encounter genetic screening scenarios involving enzyme deficiencies, focus on the distinction between laboratory findings and clinical significance. This question tests your understanding of how genetic variants can affect test results without causing disease. The scenario describes a classic example of pseudodeficiency alleles—genetic variants that reduce enzyme activity in laboratory assays but don't cause clinical symptoms. Both parents carry both a true pathogenic allele and a pseudodeficiency allele in the biotinidase gene. This creates a testing challenge because the pseudodeficiency allele can make screening results difficult to interpret, even though it's clinically benign. This perfectly illustrates option A: the challenge of distinguishing clinically significant alleles from benign variants that confound screening tests. Option B (variable expressivity) is incorrect because this involves people with identical genotypes showing different clinical presentations—not the case here, where we're dealing with different types of alleles. Option C (population-specific carrier frequencies) doesn't fit because the scenario isn't about risk assessment calculations or population differences. Option D (mosaicism) is wrong because mosaicism involves having different genetic cell lines within one individual, whereas this scenario involves inherited variants present in all cells. For genetics exams, remember that pseudodeficiency alleles are a recurring theme in newborn screening. Always distinguish between variants that affect laboratory enzyme activity versus those that cause actual clinical disease. This distinction is crucial for genetic counseling and patient management.

Question 4

1. The high carrier frequency in the Ashkenazi Jewish population.
2. The partner's negative carrier screen result.
3. The high detection rate of the enzyme-based screening. (correct answer)
4. The autosomal recessive inheritance pattern of the disease.

Explanation: While all factors are relevant, the high detection rate (>98%) of the enzyme-based screen for the woman dramatically reduces her carrier risk from 1/30 to a very small residual risk (approximately 1/1500). The partner's risk is already low (1/300) and is also reduced by his negative screen. Because the woman's initial risk was the highest component of the pre-test risk, the high efficacy of her test provides the most significant reduction and is the most important factor in determining their final (very low) residual risk. The other factors set the baseline but the high detection rate is what drives the final risk to a negligible level.

Question 5

1. 1/2
2. 2/3
3. 1/4
4. 1/3 (correct answer)

Explanation: When you encounter genetics problems involving carrier probability, you need to carefully trace inheritance patterns and distinguish between prior probability (before testing) and posterior probability (after testing results). To find this woman's prior carrier probability, trace the inheritance path from her affected uncle. Since cystic fibrosis is autosomal recessive, her uncle has genotype ff. This means both of her paternal grandparents must be carriers (Ff) to have produced an affected child. Her father inherited one allele from each grandparent. Since each grandparent has a 50% chance of passing the f allele, her father has a $\frac{1}{2}$ probability of being a carrier. If her father is a carrier and her mother is from the general population (very low carrier probability), then the woman has a $\frac{1}{2} \times \frac{1}{2} = \frac{1}{4}$ chance of inheriting the f allele from her father. However, we know she's unaffected, so she's either FF or Ff. Using conditional probability: among unaffected individuals with her family history, $\frac{1}{3}$ are carriers and $\frac{2}{3}$ are homozygous normal. Choice A ($\frac{1}{2}$) incorrectly assumes she definitely inherited an allele from a carrier father. Choice B ($\frac{2}{3}$) represents the probability she's not a carrier given she's unaffected. Choice C ($\frac{1}{4}$) is the unconditional probability before considering her unaffected status. Remember: prior probability considers family history but not test results. Always condition on known phenotypes when calculating carrier risks in genetics problems.

Question 6

1. 1/2,500
2. 1/9,640
3. 1/24,100 (correct answer)
4. 1/25,000

Explanation: The correct answer requires a multi-step risk calculation. First, calculate the woman's posterior risk of being a carrier after a negative test using Bayes' theorem. Her prior risk is 1/25. P(Carrier|Negative Test) = [P(Negative|Carrier) * P(Carrier)] / [P(Negative|Carrier) * P(Carrier) + P(Negative|Not Carrier) * P(Not Carrier)]. This is [(0.10 * 1/25)] / [(0.10 * 1/25) + (1.0 * 24/25)] = (0.1/25) / (24.1/25) ≈ 1/241. Her partner's risk remains the population risk, 1/25. The risk for an affected child is P(woman is carrier) × P(man is carrier) × 1/4 = (1/241) × (1/25) × (1/4) = 1/24,100.

Question 7

1. the carrier state itself is associated with a direct health risk to the female carrier. (correct answer)
2. the condition only affects males, while females are exclusively carriers.
3. the premutation is unstable and can expand to a full mutation only when passed through the father.
4. the carrier screening test has a lower detection rate than for autosomal recessive conditions.

Explanation: Unlike most autosomal recessive conditions where carriers are typically asymptomatic, female carriers of the fragile X premutation are at an increased risk for developing health conditions themselves, such as FXPOI and fragile X-associated tremor/ataxia syndrome (FXTAS). This is a critical counseling point that distinguishes it from conditions like CF or Tay-Sachs, where the counseling focus is almost exclusively on reproductive risk. B is incorrect as females can be affected by the full mutation. C is incorrect as expansion occurs when passed through the mother.

Question 8

1. Reassure them that being a carrier is common and rarely causes health problems, so they should not worry.
2. Explore their understanding of what being a 'carrier' means and their specific concerns about passing on the variant. (correct answer)
3. Recommend preimplantation genetic testing (PGT) to select an embryo that is not a carrier to address their concern.
4. Explain the cost and limitations of testing their child after birth to confirm carrier status.

Explanation: The core of non-directive counseling is to facilitate the patient's own decision-making by ensuring they have a clear understanding of the information and have explored their own values and feelings. The couple's distress indicates a potential misunderstanding or significant anxiety about the meaning of carrier status. The most appropriate initial step is to explore their feelings and the source of their concern (B), rather than immediately reassuring them (A), recommending a specific action (C), or shifting the focus to future testing (D).

Question 9

1. The patient is definitively not a carrier for alpha-thalassemia.
2. The patient might be a carrier for beta-thalassemia instead of alpha-thalassemia.
3. The result is uninformative, and the patient's risk remains the same as the general population risk.
4. The patient has a significantly reduced likelihood of being a carrier, but it is not ruled out completely. (correct answer)

Explanation: When you encounter questions about genetic screening tests, remember that most screening methods have limitations in sensitivity and specificity. This question tests your understanding of how to interpret negative screening results in the context of population genetics. Alpha-thalassemia carriers often show microcytosis (low MCV) because reduced alpha-globin production leads to smaller, less hemoglobin-filled red blood cells. However, this relationship isn't absolute. A normal MCV in a Southeast Asian patient significantly reduces the probability they're an alpha-thalassemia carrier, but doesn't eliminate it entirely. Some carriers, particularly those with milder mutations or certain genetic variants, may maintain normal red blood cell indices. This is why molecular testing remains the gold standard for definitive carrier detection. Choice A is wrong because screening tests, especially indirect ones like MCV, cannot provide 100% certainty. There's always some possibility of false negatives. Choice B misses the point entirely—the question asks specifically about alpha-thalassemia carrier status, and a normal MCV doesn't redirect suspicion toward beta-thalassemia. Choice C is incorrect because the normal MCV does provide meaningful information that reduces the patient's likelihood of being a carrier below the baseline population risk. Choice D correctly captures that while the normal MCV is reassuring and significantly lowers the probability of carrier status, it cannot completely rule out the possibility due to the inherent limitations of using MCV as a screening tool. Remember: negative screening results reduce risk but rarely eliminate it completely, especially when using indirect biomarkers rather than direct genetic testing.

Question 10

1. 1/150
2. 1/300 (correct answer)
3. 1/400
4. 1/10,000

Explanation: First, calculate the carrier frequency from the incidence using the Hardy-Weinberg principle. Incidence (q²) = 1/10,000, so the allele frequency (q) = 1/100. The carrier frequency (2pq) is approximately 2q = 2(1/100) = 1/50. The man has an affected sister, meaning their parents were both carriers. His risk of being a carrier is 2/3 (genotypes AA, Aa, aA are possible; he is unaffected). His partner's risk is the population risk, 1/50. The final risk for an affected child is P(man is carrier) × P(woman is carrier) × 1/4 = (2/3) × (1/50) × (1/4) = 2/600 = 1/300.

Question 11

1. The couple has a 25% risk of having a child affected with a genetic disorder and should consider prenatal diagnosis.
2. Since both parents are carriers for different conditions, their children are not at risk for either CAH or MCADD.
3. Their children have a 50% chance of being a carrier for CAH and a 50% chance of being a carrier for MCADD, but no risk of being affected by either. (correct answer)
4. There is a 1 in 4 chance that their child will be a carrier for both conditions simultaneously, but the risk for an affected child is negligible.

Explanation: For a child to be affected with an autosomal recessive condition, both parents must be carriers for the same condition. In this case, the parents are carriers for two different autosomal recessive disorders. Therefore, they cannot have a child affected with either CAH or MCADD. However, the father has a 50% chance of passing on his CAH allele, and the mother has a 50% chance of passing on her MCADD allele. This makes statement C the most accurate description of their risk.

Question 12

1. The probability that they both inherited the same pathogenic allele from one of their shared grandparents is 1/8.
2. They each have a 1/4 chance of being a carrier for any given recessive allele present in their shared grandparents.
3. The risk is doubled because there are two shared great-grandparents from whom they could inherit alleles.
4. Their child's coefficient of inbreeding is 1/16, representing the probability of inheriting an allele that is identical by descent. (correct answer)

Explanation: When you encounter genetics problems involving consanguineous mating (relatives having children), focus on the coefficient of inbreeding, which quantifies the probability that an individual inherits two copies of the same allele that are identical by descent from a common ancestor. For first cousins, you can calculate this coefficient by tracing inheritance paths. First cousins share one set of grandparents, and there are two possible paths for an allele to travel from a shared grandparent to their child: through each of the cousins' parents. Each step in inheritance has a $\frac{1}{2}$ probability. The path from shared grandparent → cousin 1's parent → cousin 1 → child has probability $(\frac{1}{2})^3$, and the path from the same grandparent → cousin 2's parent → cousin 2 → child also has probability $(\frac{1}{2})^3$. Since there are two shared grandparents, the total coefficient is $2 \times (\frac{1}{2})^3 \times (\frac{1}{2})^3 = 2 \times \frac{1}{64} = \frac{1}{16}$. This represents the increased risk for any autosomal recessive condition. Choice A incorrectly calculates $\frac{1}{8}$ as the probability both cousins inherited the same allele, but this doesn't account for the child's inheritance. Choice B describes individual carrier risk ($\frac{1}{4}$) but doesn't combine this properly for the mating. Choice C incorrectly doubles risk based on two grandparents without proper probability calculations. Remember: For consanguinity problems, always calculate the coefficient of inbreeding using inheritance path probabilities. This directly gives you the quantitative increased risk for recessive conditions.

Question 13

1. 1/4
2. 1/51
3. 1/102 (correct answer)
4. 1/200

Explanation: The woman's prior probability of being a carrier is 1/2, as her mother is a carrier. A negative test modifies this risk. Using Bayes' theorem, her posterior carrier risk is P(C|neg) = [P(neg|C)P(C)] / [P(neg|C)P(C) + P(neg|~C)P(~C)] = [(0.02)(0.5)] / [(0.02)(0.5) + (1)(0.5)] = 0.01 / 0.51 ≈ 1/51. The risk for her son to be affected is her probability of being a carrier multiplied by the 1/2 chance of passing on the affected X chromosome. Thus, the risk is (1/51) × (1/2) = 1/102.

Question 14

1. All first-degree and second-degree relatives should be tested concurrently to maximize detection.
2. The patient's siblings should be tested first, as they each have a 50% chance of being a carrier. (correct answer)
3. The patient's parents should be tested to determine the origin of the variant before testing other relatives.
4. The first cousins should be prioritized as they are less likely to have been informed of the family risk.

Explanation: Cascade screening is a stepwise process that starts with the closest relatives of the identified individual (the proband). First-degree relatives (siblings, parents, children) are at the highest risk. In this case, the siblings each have a 50% chance of inheriting the same variant and being carriers. Testing them is the most efficient next step. Testing parents (C) can be useful but testing siblings directly addresses the risk in the same generation. Testing all relatives concurrently (A) is inefficient. Prioritizing more distant relatives like cousins (D) over closer ones is illogical and contrary to the cascade screening principle.

Question 15

1. 1/2
2. 2/3
3. 1/4
4. 1/3 (correct answer)

Explanation: When you encounter genetics problems involving carrier probability, you need to carefully trace inheritance patterns and distinguish between prior probability (before testing) and posterior probability (after testing results). To find this woman's prior carrier probability, trace the inheritance path from her affected uncle. Since cystic fibrosis is autosomal recessive, her uncle has genotype ff. This means both of her paternal grandparents must be carriers (Ff) to have produced an affected child. Her father inherited one allele from each grandparent. Since each grandparent has a 50% chance of passing the f allele, her father has a $\frac{1}{2}$ probability of being a carrier. If her father is a carrier and her mother is from the general population (very low carrier probability), then the woman has a $\frac{1}{2} \times \frac{1}{2} = \frac{1}{4}$ chance of inheriting the f allele from her father. However, we know she's unaffected, so she's either FF or Ff. Using conditional probability: among unaffected individuals with her family history, $\frac{1}{3}$ are carriers and $\frac{2}{3}$ are homozygous normal. Choice A ($\frac{1}{2}$) incorrectly assumes she definitely inherited an allele from a carrier father. Choice B ($\frac{2}{3}$) represents the probability she's not a carrier given she's unaffected. Choice C ($\frac{1}{4}$) is the unconditional probability before considering her unaffected status. Remember: prior probability considers family history but not test results. Always condition on known phenotypes when calculating carrier risks in genetics problems.

Question 16

1. 1/2,500
2. 1/9,640
3. 1/24,100 (correct answer)
4. 1/25,000

Explanation: The correct answer requires a multi-step risk calculation. First, calculate the woman's posterior risk of being a carrier after a negative test using Bayes' theorem. Her prior risk is 1/25. P(Carrier|Negative Test) = [P(Negative|Carrier) * P(Carrier)] / [P(Negative|Carrier) * P(Carrier) + P(Negative|Not Carrier) * P(Not Carrier)]. This is [(0.10 * 1/25)] / [(0.10 * 1/25) + (1.0 * 24/25)] = (0.1/25) / (24.1/25) ≈ 1/241. Her partner's risk remains the population risk, 1/25. The risk for an affected child is P(woman is carrier) × P(man is carrier) × 1/4 = (1/241) × (1/25) × (1/4) = 1/24,100.

Question 17

1. 1/150
2. 1/300 (correct answer)
3. 1/400
4. 1/10,000

Explanation: First, calculate the carrier frequency from the incidence using the Hardy-Weinberg principle. Incidence (q²) = 1/10,000, so the allele frequency (q) = 1/100. The carrier frequency (2pq) is approximately 2q = 2(1/100) = 1/50. The man has an affected sister, meaning their parents were both carriers. His risk of being a carrier is 2/3 (genotypes AA, Aa, aA are possible; he is unaffected). His partner's risk is the population risk, 1/50. The final risk for an affected child is P(man is carrier) × P(woman is carrier) × 1/4 = (2/3) × (1/50) × (1/4) = 2/600 = 1/300.

Question 18

1. The high carrier frequency in the Ashkenazi Jewish population.
2. The partner's negative carrier screen result.
3. The high detection rate of the enzyme-based screening. (correct answer)
4. The autosomal recessive inheritance pattern of the disease.

Explanation: While all factors are relevant, the high detection rate (>98%) of the enzyme-based screen for the woman dramatically reduces her carrier risk from 1/30 to a very small residual risk (approximately 1/1500). The partner's risk is already low (1/300) and is also reduced by his negative screen. Because the woman's initial risk was the highest component of the pre-test risk, the high efficacy of her test provides the most significant reduction and is the most important factor in determining their final (very low) residual risk. The other factors set the baseline but the high detection rate is what drives the final risk to a negligible level.

Question 19

1. The patient is definitively not a carrier for alpha-thalassemia.
2. The patient might be a carrier for beta-thalassemia instead of alpha-thalassemia.
3. The result is uninformative, and the patient's risk remains the same as the general population risk.
4. The patient has a significantly reduced likelihood of being a carrier, but it is not ruled out completely. (correct answer)

Explanation: When you encounter questions about genetic screening tests, remember that most screening methods have limitations in sensitivity and specificity. This question tests your understanding of how to interpret negative screening results in the context of population genetics. Alpha-thalassemia carriers often show microcytosis (low MCV) because reduced alpha-globin production leads to smaller, less hemoglobin-filled red blood cells. However, this relationship isn't absolute. A normal MCV in a Southeast Asian patient significantly reduces the probability they're an alpha-thalassemia carrier, but doesn't eliminate it entirely. Some carriers, particularly those with milder mutations or certain genetic variants, may maintain normal red blood cell indices. This is why molecular testing remains the gold standard for definitive carrier detection. Choice A is wrong because screening tests, especially indirect ones like MCV, cannot provide 100% certainty. There's always some possibility of false negatives. Choice B misses the point entirely—the question asks specifically about alpha-thalassemia carrier status, and a normal MCV doesn't redirect suspicion toward beta-thalassemia. Choice C is incorrect because the normal MCV does provide meaningful information that reduces the patient's likelihood of being a carrier below the baseline population risk. Choice D correctly captures that while the normal MCV is reassuring and significantly lowers the probability of carrier status, it cannot completely rule out the possibility due to the inherent limitations of using MCV as a screening tool. Remember: negative screening results reduce risk but rarely eliminate it completely, especially when using indirect biomarkers rather than direct genetic testing.

Question 20

1. The probability that they both inherited the same pathogenic allele from one of their shared grandparents is 1/8.
2. They each have a 1/4 chance of being a carrier for any given recessive allele present in their shared grandparents.
3. The risk is doubled because there are two shared great-grandparents from whom they could inherit alleles.
4. Their child's coefficient of inbreeding is 1/16, representing the probability of inheriting an allele that is identical by descent. (correct answer)

Explanation: When you encounter genetics problems involving consanguineous mating (relatives having children), focus on the coefficient of inbreeding, which quantifies the probability that an individual inherits two copies of the same allele that are identical by descent from a common ancestor. For first cousins, you can calculate this coefficient by tracing inheritance paths. First cousins share one set of grandparents, and there are two possible paths for an allele to travel from a shared grandparent to their child: through each of the cousins' parents. Each step in inheritance has a $\frac{1}{2}$ probability. The path from shared grandparent → cousin 1's parent → cousin 1 → child has probability $(\frac{1}{2})^3$, and the path from the same grandparent → cousin 2's parent → cousin 2 → child also has probability $(\frac{1}{2})^3$. Since there are two shared grandparents, the total coefficient is $2 \times (\frac{1}{2})^3 \times (\frac{1}{2})^3 = 2 \times \frac{1}{64} = \frac{1}{16}$. This represents the increased risk for any autosomal recessive condition. Choice A incorrectly calculates $\frac{1}{8}$ as the probability both cousins inherited the same allele, but this doesn't account for the child's inheritance. Choice B describes individual carrier risk ($\frac{1}{4}$) but doesn't combine this properly for the mating. Choice C incorrectly doubles risk based on two grandparents without proper probability calculations. Remember: For consanguinity problems, always calculate the coefficient of inbreeding using inheritance path probabilities. This directly gives you the quantitative increased risk for recessive conditions.